Self-Reported Walking Limitation Increases Five-Year Fracture Risk
24 Jan 2024
Clinical ResultClinical Study
WEDNESDAY, Jan. 24, 2024 -- Walking limitation is significantly associated with five-year fracture risk, according to a study published online Jan. 23 in JAMA Network Open.
Dana Bliuc, Ph.D., from the Garvan Institute of Medical Research in Darlinghurst, Australia, and colleagues examined the association between a self-reported walking limitation of ≤1,000 m and five-year risk for fracture among 266,912 participants in the 45 and Up Study.
The researchers found that approximately 20 percent of participants reported a degree of limitation in walking ≤1,000 m at baseline, and during a mean follow-up of 4.1 years, 7,190 women and 4,267 men experienced an incident fracture. Both a little limitation and a lot of limitation were associated with a higher risk for fracture in both men and women compared with participants who reported no walking limitations (a little limitation among women: hazard ratio [HR], 1.32; a little limitation among men: HR, 1.46; a lot of limitation among women: HR, 1.60; a lot of limitation among men: HR, 2.03). Six in 10 fractures were attributable to walking limitations. This association was significant for hip, vertebral, and nonhip nonvertebral fracture, with risk ranging from 21 percent to more than 219 percent.
"In this study, self-reported walking limitations were common; given that they are easily detected, they should be sought by clinicians to identify high-risk candidates for further bone assessment," the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Abstract/Full Text
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Posted January 2024
More news resources
FDA Medwatch Drug Alerts
Daily MedNews
News for Health Professionals
New Drug Approvals
New Drug Applications
Drug Shortages
Clinical Trial Results
Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.